|Source||Humanized (from mouse)|
|Pronunciation||moe gam" ue liz' ue mab|
|Main uses||Mycosis fungoides, Sézary disease|
|Side effects||Rash, pneumonia, fever, cellulitis|
|Chemical and physical data|
|Molar mass||146444.95 g·mol−1|
Mogamulizumab, sold under the brand name Poteligeo, is a medication used to treat mycosis fungoides and Sézary disease. It is used when other treatments are not effective. It is given by gradual injection into a vein.
Common side effects include rash, pneumonia, fever, and cellulitis. Other side effects may include Stevens-Johnson syndrome, sepsis, pneumonitis, myocarditis, and polymyositis. Use in pregnancy may harm the baby. It is a monoclonal antibody that binds to CC chemokine receptor 4 (CCR4) found on white blood cells.
Mogamulizumab was approved for medical use in the United States and Europe in 2018. In the United Kingdom 4 mg cost the NHS about £1,300 as of 2021. This amount in the United States costs about 4,200 USD.
It was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014, for relapsed or refractory CCR4+ cutaneous T cell lymphoma (CTCL). The latter approval was based on study with 28 subjects.
It is given at a dose of 1 mg/kg once a week for 4 weeks than once every two weeks.
The precursor to mogamulizumab was a mouse anti-human CCR4 IgG1 mAb (KM2160), that was made in 1996 in a collaboration between Kouji Matsushima of University of Tokyo and Kyowa Hakko Kirin. Kyowa humanized it, and expressed the humanized gene in a CHO cell line in which FUT8 had been knocked out, which produced antibodies with no fucose in the Fc region.  This is thought to enhance its antibody-dependent cell-mediated cytotoxicity. It was first tested in humans in 2007.
Kyowa licensed rights for use outside of cancer to Amgen in 2008, for $100 million up front and $420 million in biodollars. Amgen ran a Phase I study to explore its use in asthma. Amgen terminated the agreement in 2014.
In 2017, the US FDA granted it a priority review for CTCL. Full approval was granted in August 2018. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Mogamulizumab is being explored as a treatment for HTLV-1–Associated Myelopathy. An early Phase 1-2a study showed decreased in proviral loads, as well as inflammatory markers in the CSF. 79% of the patients showed reduction in spasticity and 32% showed decrease in motor disability.
- "Mogamulizumab-kpkc Monograph for Professionals". Drugs.com. Archived from the original on 6 August 2020. Retrieved 18 November 2021.
- "Poteligeo". Archived from the original on 5 July 2021. Retrieved 18 November 2021.
- "Poteligeo". Therapeutic Goods Administration (TGA). 15 February 2021. Archived from the original on 9 September 2021. Retrieved 8 September 2021.
- "AusPAR: Mogamulizumab". Therapeutic Goods Administration (TGA). 10 May 2021. Archived from the original on 9 September 2021. Retrieved 8 September 2021.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 920. ISBN 978-0857114105.
- "Poteligeo Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 11 April 2021. Retrieved 18 November 2021.
- Yu X, Marshall MJ, Cragg MS, Crispin M (June 2017). "Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering" (PDF). BioDrugs. 31 (3): 151–166. doi:10.1007/s40259-017-0223-8. PMID 28466278. S2CID 3722081. Archived (PDF) from the original on 2021-08-26. Retrieved 2021-09-09.
- Broccoli A, Argnani L, Zinzani PL (November 2017). "Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease". Cancer Treatment Reviews. 60: 120–129. doi:10.1016/j.ctrv.2017.09.002. PMID 28946015.
- Ueda R (2015). "Clinical Application of Anti-CCR4 Monoclonal Antibody". Oncology. 89 Suppl 1: 16–21. doi:10.1159/000431059. PMID 26550987. S2CID 24091636.
- "Available Agents: Mogamulizumab". NCI Formulary. Archived from the original on 11 May 2018. Retrieved 11 May 2018.
- Carroll J (August 25, 2017). "After a long clinical odyssey, the FDA tapped this PhIII anti-CCR4 as a 'breakthrough' lymphoma drug". Endpoints. Archived from the original on October 31, 2021. Retrieved September 9, 2021.
- Pease JE, Horuk R (May 2014). "Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4". Expert Opinion on Drug Discovery. 9 (5): 467–83. doi:10.1517/17460441.2014.897324. PMID 24641500. S2CID 32596704.
- Adamson L (22 January 2018). "Mogamulizumab Receives Priority Review for CTCL - ASH Clinical News". ASH Clinical News. Archived from the original on 10 May 2018. Retrieved 9 September 2021.
- "FDA approves treatment for two rare types of non-Hodgkin lymphoma" (Press release). Archived from the original on 2021-07-15. Retrieved 2021-09-09.
- New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Archived from the original on 17 September 2020. Retrieved 16 September 2020.
- Sato T, Coler-Reilly AL, Yagishita N, Araya N, Inoue E, Furuta R, et al. (February 2018). "Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy". The New England Journal of Medicine. 378 (6): 529–538. doi:10.1056/NEJMoa1704827. PMID 29414279.